AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11195315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone resorption markers in OA
Number of subjects: 60
Study 11195315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone formation markers in OA
Number of subjects: 60
Study 11195315 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-OA)
Number of subjects: 60
Study 9064269 — intervention group
Group type: EXPERIMENTAL
Intervention: thiamine/pyridoxine
Number of subjects: 303
Study 9064269 — intervention group
Group type: EXPERIMENTAL
Intervention: benfotiamine/pyridoxine
Number of subjects: 303
Study 9064269 — intervention group
Group type: EXPERIMENTAL
Intervention: nucleotides of cytidine and uridine
Number of subjects: 303
Study 9064269 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 303
Study 1478796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-carnitine
Number of subjects: 2
Study 1478796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 6719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 6719982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acebutolol and nifedipine
Number of subjects: 0
Study 28861729 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm, 2 W, pulse interval 200 μs; pulse length 100 μs, 400-μm initiated fiber tip)
Number of subjects: 18
Study 28861729 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (control)
Number of subjects: 18
Study 26045552 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrtus communis L. freeze-dried aqueous extract (1000 mg/d)
Number of subjects: 45
Study 26045552 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazol (20 mg/d)
Number of subjects: 45
Study 26045552 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Myrtus communis and Omeprazol
Number of subjects: 45
Study 26045552 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 45
Study 25457739 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 434
Study 25457739 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapies
Number of subjects: 434
Study 22481696 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter VRP1®
Number of subjects: 10
Study 22481696 — intervention group
Group type: EXPERIMENTAL
Intervention: ELTGOL
Number of subjects: 10
Study 22481696 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 20103724 — intervention group
Group type: COMPARATOR
Intervention: Topical perillyl alcohol (POH) cream, low dose (0.76% w/w)
Number of subjects: 0
Study 20103724 — intervention group
Group type: COMPARATOR
Intervention: Topical perillyl alcohol (POH) cream, high dose
Number of subjects: 0
Study 18054632 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge transconjunctival sutureless vitrectomy
Number of subjects: 57
Study 18054632 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge standard vitrectomy
Number of subjects: 57
Study 16140708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day for 4 weeks, followed by lovastatin 40 mg/day for 20 weeks
Number of subjects: 54
Study 16140708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 54
Study 16140708 — intervention group
Group type: COMPARATOR
Intervention: Diet plus placebo
Number of subjects: 54
Study 11849912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolution under fed conditions with dietary components
Number of subjects: 0
Study 11849912 — intervention group
Group type: COMPARATOR
Intervention: Dissolution under fasting conditions
Number of subjects: 0
Study 11849912 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro modeling of in vivo conditions
Number of subjects: 0
Study 11783228 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenlian Ear-Drops (SLED), three times per day
Number of subjects: 201
Study 11783228 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin ear-drop, three times per day
Number of subjects: 201
Study 7723442 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter AIDS Clinical Group Trials (n = 1,907)
Number of subjects: 2112
Study 7723442 — intervention group
Group type: COMPARATOR
Intervention: Nontrial sample (n = 205)
Number of subjects: 2112
Study 2190900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyroglutamic acid (PCA)
Number of subjects: 40
Study 2190900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30990099 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring containing ethinylestradiol 3.47 mg and etonogestrel 11.00 mg
Number of subjects: 58
Study 30990099 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive vaginal ring containing ethinylestradiol 2.7 mg and etonogestrel 11.7 mg
Number of subjects: 58
Study 29649978 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized objects (e.g., cigarette, paper)
Number of subjects: 21
Study 29649978 — intervention group
Group type: COMPARATOR
Intervention: Non-personalized objects
Number of subjects: 21
Study 27444570 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace conditioning paradigm using neutral tones as CS+ and alerting sounds as UCS
Number of subjects: 29
Study 24268886 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT administered at baseline with a cut-point of 8 or above
Number of subjects: 1325
Study 24268886 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT administered at baseline
Number of subjects: 1325
Study 24268886 — intervention group
Group type: EXPERIMENTAL
Intervention: High expectations to drink post-release
Number of subjects: 1325
Study 24268886 — intervention group
Group type: EXPERIMENTAL
Intervention: Past amphetamine-type stimulant (ATS) use
Number of subjects: 1325
Study 22433034 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloy Primer (AP)
Number of subjects: 60
Study 22433034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 M NaOH
Number of subjects: 60
Study 22433034 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐Primer Plus (ZP)
Number of subjects: 60
Study 22433034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 M NaOH + Alloy Primer (NaOH-AP)
Number of subjects: 60
Study 22433034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 M NaOH + Z‐Primer Plus (NaOH-ZP)
Number of subjects: 60
Study 22433034 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group) (CR)
Number of subjects: 60
Study 20708496 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (20 min of daily exercise in the classroom)
Number of subjects: 4700
Study 20708496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4700
Study 18570266 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Pycnogenol per day at meals
Number of subjects: 100
Study 18570266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15852988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% halothane
Number of subjects: 75
Study 15852988 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 75
Study 15852988 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane
Number of subjects: 75
Study 12704070 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU polymer wafers
Number of subjects: 20
Study 12704070 — intervention group
Group type: COMPARATOR
Intervention: Control wafers
Number of subjects: 20
Study 10074011 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplemented formula milk
Number of subjects: 100
Study 10074011 — intervention group
Group type: COMPARATOR
Intervention: Unmodified cows' milk
Number of subjects: 100
Study 8933551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10(6) pfu RRV‐TV
Number of subjects: 195
Study 8933551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10(5) pfu RRV‐TV
Number of subjects: 195
Study 8933551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 8933551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10(6) pfu RRV‐TV (older infants)
Number of subjects: 195
Study 8933551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10(5) pfu RRV‐TV (older infants)
Number of subjects: 195
Study 8933551 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 10(5) pfu RRV‐TV (younger infants)
Number of subjects: 195
Study 1906830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg estriol vaginal tablets
Number of subjects: 15
Study 1906830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 15
Study 6227756 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim at night
Number of subjects: 64
Study 6227756 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg methenamine hippurate every 12 hours
Number of subjects: 64
Study 6227756 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine solution, cleansing twice daily
Number of subjects: 64
Study 30712751 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (60 minutes per session, three sessions per week for two months)
Number of subjects: 62
Study 28225475 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 50
Study 28225475 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary lifestyle)
Number of subjects: 50
Study 25684277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 25684277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 0
Study 24365961 — intervention group
Group type: EXPERIMENTAL
Intervention: BeZuHG (early discharge followed by home treatment service)
Number of subjects: 100
Study 24365961 — intervention group
Group type: COMPARATOR
Intervention: TAU (regular inpatient stay)
Number of subjects: 100
Study 22930458 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial surgical ablation (group A)
Number of subjects: 224
Study 22930458 — intervention group
Group type: COMPARATOR
Intervention: No ablation (group B)
Number of subjects: 224
Study 19476473 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 335
Study 19476473 — intervention group
Group type: COMPARATOR
Intervention: Metformin (titrated to 1500 mg daily)
Number of subjects: 335
Study 19476473 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 335
Study 19476473 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 335
Study 17502494 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (3.3 to 55 pmol/min per 1000 mL forearm volume)
Number of subjects: 18
Study 17502494 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (55 pmol/1000 mL per min)
Number of subjects: 18
Study 17502494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fludrocortisone (0.3 mg/d for 2 weeks)
Number of subjects: 18
Study 15343450 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal transplant after penetrating eye injury (study group S)
Number of subjects: 44
Study 15343450 — intervention group
Group type: COMPARATOR
Intervention: Corneal transplant in patients with Fuchs' endothelial dystrophy (control group K)
Number of subjects: 44
Study 11641371 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ribose supplementation (4 doses/day at 4 g/dose)
Number of subjects: 19
Study 11641371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9734766 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 0
Study 9734766 — intervention group
Group type: COMPARATOR
Intervention: Incremental bolus of propofol
Number of subjects: 0
Study 7989402 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate syrup 70 mg/ml administered 20-40 min prior to procedure
Number of subjects: 596
Study 2643443 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 113
Study 2643443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 113
Study 2643443 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 113
Study 2643443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 29173214 — intervention group
Group type: EXPERIMENTAL
Intervention: Text warnings
Number of subjects: 215
Study 29173214 — intervention group
Group type: COMPARATOR
Intervention: Ultra-processed food images
Number of subjects: 215
Study 26823240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60
Study 26823240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 60
Study 26823240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine N-butylbromide (HnBB)
Number of subjects: 60
Study 26823240 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 25640116 — intervention group
Group type: EXPERIMENTAL
Intervention: Human breast milk (HBM)
Number of subjects: 0
Study 25640116 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment
Number of subjects: 0
Study 24006749 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria jam enriched with chromium (20 g daily containing 280 microg of iodine and 66 microg of chromium)
Number of subjects: 50
Study 24006749 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria jam enriched with chromium
Number of subjects: 50
Study 24006749 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (comparison group)
Number of subjects: 50
Study 21106985 — intervention group
Group type: EXPERIMENTAL
Intervention: Autografting (n = 112)
Number of subjects: 223
Study 21106985 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 111)
Number of subjects: 223
Study 21106985 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 223
Study 18356327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol-containing dark chocolate bar with added sterol esters (1.1 g sterol esters per bar)
Number of subjects: 49
Study 18356327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol-containing dark chocolate bar
Number of subjects: 49
Study 16214598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg to 45 mg)
Number of subjects: 5238
Study 16214598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study 16214598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238
Study 12352276 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 15
Study 12352276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10408591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 34
Study 10408591 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 34
Study 10408591 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with diuretic (hydrochlorothiazide)
Number of subjects: 34
Study 10408591 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACE inhibitors
Number of subjects: 34
Study 7580638 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 1312
Study 7580638 — intervention group
Group type: EXPERIMENTAL
Intervention: Current users of tamoxifen
Number of subjects: 1312
Study 7580638 — intervention group
Group type: COMPARATOR
Intervention: Non-users of tamoxifen
Number of subjects: 1312
Study 1979188 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis followed by reinfusion of unfrozen autologous plasma
Number of subjects: 0
Study 1979188 — intervention group
Group type: COMPARATOR
Intervention: Medicamentous treatment alone (control group)
Number of subjects: 0
Study 7015540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 60
Study 7015540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 60
Study 7015540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30586698 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) pump
Number of subjects: 361
Study 30586698 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII) pump
Number of subjects: 361
Study 30586698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke events (any type)
Number of subjects: 361
Study 28056024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg albendazole
Number of subjects: 1010
Study 28056024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010
Study 28056024 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg albendazole (for STH-positive mothers)
Number of subjects: 1010
Study 28056024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for STH-positive mothers)
Number of subjects: 1010
Study 25900659 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% inspired oxygen
Number of subjects: 555
Study 25900659 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% inspired oxygen
Number of subjects: 555
Study 25900659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 555
Study 25900659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 23373620 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg aspirin for 30 days and 180 mg ticagrelor for 1 year
Number of subjects: 632
Study 23373620 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet regimen
Number of subjects: 632
Study 21294929 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 8
Study 21294929 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylose (50 g)
Number of subjects: 8
Study 21294929 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study 19696440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual house dust mite (HDM) immunotherapy
Number of subjects: 30
Study 19696440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17355733 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg once daily for 6 months)
Number of subjects: 81
Study 17355733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily oral for 6 months)
Number of subjects: 81
Study 15083446 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles with subtalar strapping (16 mm elevation)
Number of subjects: 62
Study 15083446 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles with subtalar strapping (12 mm elevation)
Number of subjects: 62
Study 15083446 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles with subtalar strapping (8 mm elevation)
Number of subjects: 62
Study 12384899 — intervention group
Group type: EXPERIMENTAL
Intervention: Recliner-chair
Number of subjects: 0
Study 12384899 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital bed
Number of subjects: 0
Study 9876598 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation and viscosity (in vitro variables)
Number of subjects: 10
Study 9876598 — intervention group
Group type: EXPERIMENTAL
Intervention: Model I (cumulative percentage of paracetamol dissolved)
Number of subjects: 10
Study 9876598 — intervention group
Group type: EXPERIMENTAL
Intervention: Model II (Weibull function parameters)
Number of subjects: 10
Study 7925528 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP/PGE1 (5 micrograms CGRP plus 10 micrograms PGE1)
Number of subjects: 68
Study 3072180 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (relaxation and biofeedback therapies)
Number of subjects: 0
Study 3072180 — intervention group
Group type: COMPARATOR
Intervention: Medicated patients
Number of subjects: 0
Study 30803434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma metabolites
Number of subjects: 0
Study 30803434 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific significant metabolites (pseudo‐uridine, indole‐3‐lactate, uric acid, isothreonic acid, and creatinine)
Number of subjects: 0
Study 28872272 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-POCT in South Africa
Number of subjects: 0
Study 28872272 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-POCT in Zambia
Number of subjects: 0
Study 28872272 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-POCT with enhanced QA interventions in South Africa
Number of subjects: 0
Study 28872272 — intervention group
Group type: COMPARATOR
Intervention: HIV-POCT
Number of subjects: 0
Study 26571887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electric stimulation
Number of subjects: 120
Study 26571887 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (estazolam 1 mg orally)
Number of subjects: 120
Study 26571887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 120
Study 23383959 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg kg(‐1))
Number of subjects: 11
Study 23383959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 ml)
Number of subjects: 11
Study 20189611 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 treatment (6 g/d)
Number of subjects: 50
Study 20189611 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 50
Study 19320241 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 83
Study 19320241 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-drug regimen
Number of subjects: 83
Study 16501728 — intervention group
Group type: EXPERIMENTAL
Intervention: Community outreach case-finding intervention
Number of subjects: 380
Study 16501728 — intervention group
Group type: COMPARATOR
Intervention: Passive case-finding in control communities
Number of subjects: 380
Study 12818245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (warfarin 10, 7.5, and 5 mg for three consecutive days)
Number of subjects: 33